Last $5.94 USD
Change Today -0.04 / -0.67%
Volume 1.3M
OREX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Stuttgart
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

3344 North Torrey Pines Court

Suite 200

La Jolla, CA 92037

United States

Phone: 858-875-8600

Fax: 858-875-8650

Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. The company’s product candidates are NB32, which has completed Phase III clinical trials and which is being studied in a cardiovascular outcomes trial, and Empatic, which has completed Phase II clinical trials. NB32 is a fixed dose combination of bupropion sustained release (SR) and naltrexone SR. The company holds patents in the United States that cover the composition of NB32 (bupropion SR and naltrexone SR), as well as the use of NB32 for the treatment of obesity. The company has also filed additional U.S. patents covering various aspects of NB32. In addition, it owns or has exclusive rights to various patent applications pending in various jurisdictions outside of the United States with respect to compositions, methods of use and formulations relating to NB32. Naltrexone was approved in the United States for the treatment of opioid addiction and for the treatment of alcoholism. It is marketed under the brand names Depade, ReVia, and in an injectable extended release formulation, Vivitrol, which was approved for the treatment of alcohol dependence and expanded to include prevention of relapse to opioid dependence. Bupropion was approved for marketing in the United States for depression, marketed under the brand name Wellbutrin, and for smoking cessation, marketed under the brand name Zyban. Bupropion is active at the neuronal uptake site for the neurotransmitters dopamine and norepinephrine. Empatic Empatic is a fixed dose combination of bupropion SR and zonisamide SR. The company holds an exclusive license to an issued U.S. patent covering the Empatic composition and methods of use in obesity, and it has filed additional patents covering various compositions, methods of use and formulations. Zonisamide immediate release was approved in the United States for the adjunctive treatment of partial seizures, a form of epilepsy. It is marketed under the brand name Zonegran by Eisai Inc. Sales and Marketing The company is developing its product candidates for large markets traditionally served by primary care physicians. The company has a collaboration agreement with Takeda Pharmaceutical Company Limited (Takeda) to develop and commercialize NB32 in the United States, Canada, and Mexico. The company retains marketing rights for NB32 outside the United States, Canada and Mexico and worldwide marketing rights for Empatic. Intellectual Property The company owns or has exclusive rights to various patent application families pending in the United States with respect to various compositions, methods of use and formulations relating to NB32 and/or Empatic. The company also has various patent applications pending in various foreign countries that correspond to some of the pending U.S. applications. NB32 is protected by U.S. patent number 7,375,111, which the company refers to as the Weber/Cowley composition patent, and U.S. patent number 7,462,626, which it refers to as the Weber/Cowley methods patent. Provided maintenance fees are paid, the Weber/Cowley composition patent is expected to expire in March 2025, and the Weber/Cowley methods patent is expected to expire in July 2024. Collectively, the company refers to the Weber/Cowley composition patent and the Weber/Cowley methods patent as the Weber/Cowley patents. Each of these stems from a provisional patent application that it owns but that is the subject of agreements with the Oregon Heath & Science University, or OHSU, and Duke University requiring it to pay them specified royalties on sales of products covered by the patent applications. The Weber/Cowley patents cover the composition of NB32 and methods of administering it to treat obesity. The company has also filed a number of international counterparts to these patent applications in foreign countries. The European Patent Office, or EPO, has granted the European version of the Weber/Cowley patent, which published as EP1617832 B1. This EP patent has issued in various countries throughout the European Union and provides coverage for NB32 until at

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OREX:US $5.94 USD -0.04

OREX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OREX.
View Industry Companies
 

Industry Analysis

OREX

Industry Average

Valuation OREX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 21.8x
Price/Book 43.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 15.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OREXIGEN THERAPEUTICS INC, please visit www.orexigen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.